RSV prevention in all infants: which is the most preferable strategy?
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …
young children that may lead to hospitalizations and a substantial number of outpatient …
Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model
A Kieffer, M Beuvelet, A Sardesai… - The Journal of …, 2022 - academic.oup.com
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …
United States, especially among infants. Nirsevimab, an investigational long-acting …
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with …
Background In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants …
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants …
Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19
Pediatric coronavirus disease 2019 (COVID-19) after SARS-CoV-2 infection is associated
with fewer hospitalizations and often milder disease than in adults. A subset of children …
with fewer hospitalizations and often milder disease than in adults. A subset of children …
4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication
The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics
against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric …
against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric …
Respiratory syncytial virus (RSV) RNA in wastewater settled solids reflects RSV clinical positivity rates
B Hughes, D Duong, BJ White… - … & Technology Letters, 2022 - ACS Publications
Wastewater-based epidemiology (WBE) uses concentrations of infectious agent targets in
wastewater to infer infection trends in the contributing community. To date, WBE has been …
wastewater to infer infection trends in the contributing community. To date, WBE has been …
Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January-September 2020: Analysis of national …
DY Oh, S Buda, B Biere, J Reiche… - The Lancet Regional …, 2021 - thelancet.com
Background During the initial COVID-19 response, Germany's Federal Government
implemented several nonpharmaceutical interventions (NPIs) that were instrumental in …
implemented several nonpharmaceutical interventions (NPIs) that were instrumental in …
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
B Ahani, KM Tuffy, AA Aksyuk, D Wilkins… - Nature …, 2023 - nature.com
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV)
fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical …
fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical …
Infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak
Importance Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract
infections (LRTIs) and infant hospitalization worldwide. Objective To evaluate the …
infections (LRTIs) and infant hospitalization worldwide. Objective To evaluate the …
Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
MT Caserta, ST O'Leary, FM Munoz, SL Ralston - Pediatrics, 2023 - publications.aap.org
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …